Business Description
Nanjing Hicin Pharmaceutical Co Ltd
ISIN : CNE100002F44
Share Class Description:
SZSE:300584: Class ACompare
Compare
Traded in other countries / regions
300584.China IPO Date
2017-01-12Description
Nanjing Hicin Pharmaceutical Co Ltd is a China-based company engaged in producing pharmaceutical preparations. In addition, it is also involved in manufacturing synthetic chemicals, conducting new drug research and development as well as technical transferring. The company produces series of the medicines such as antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for the cardio-cerebral system and immuno-modulate agents. The active pharmaceutical ingredients, omeprazole sodium for injection, cefepime hydrochloride for Injection and lansoprazole tablets are exported by the firm into South-Asian countries, South-American countries and European countries.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.07 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.27 | |||||
| Debt-to-EBITDA | 5.54 | |||||
| Interest Coverage | 6.84 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.28 | |||||
| Beneish M-Score | -2.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9.8 | |||||
| 3-Year EBITDA Growth Rate | -0.2 | |||||
| 3-Year EPS without NRI Growth Rate | -11.3 | |||||
| 3-Year FCF Growth Rate | -54.8 | |||||
| 3-Year Book Growth Rate | 13.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.14 | |||||
| 9-Day RSI | 53.61 | |||||
| 14-Day RSI | 53.69 | |||||
| 6-1 Month Momentum % | -40.7 | |||||
| 12-1 Month Momentum % | -34.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.91 | |||||
| Quick Ratio | 0.68 | |||||
| Cash Ratio | 0.05 | |||||
| Days Inventory | 306.48 | |||||
| Days Sales Outstanding | 134.77 | |||||
| Days Payable | 257.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -3.41 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.3 | |||||
| Operating Margin % | 11.43 | |||||
| Net Margin % | 7.42 | |||||
| FCF Margin % | -34.37 | |||||
| ROE % | 3.83 | |||||
| ROA % | 2.75 | |||||
| ROIC % | 4.34 | |||||
| ROC (Joel Greenblatt) % | 6.22 | |||||
| ROCE % | 4.86 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 57.06 | |||||
| PE Ratio without NRI | 47.88 | |||||
| Shiller PE Ratio | 24.81 | |||||
| PS Ratio | 4.26 | |||||
| PB Ratio | 2.14 | |||||
| Price-to-Tangible-Book | 2.57 | |||||
| EV-to-EBIT | 49.27 | |||||
| EV-to-EBITDA | 49.27 | |||||
| EV-to-Revenue | 4.76 | |||||
| EV-to-FCF | -14.22 | |||||
| Price-to-Projected-FCF | 18.41 | |||||
| Price-to-Graham-Number | 2.34 | |||||
| Earnings Yield (Greenblatt) % | 2.03 | |||||
| FCF Yield % | -8.1 | |||||
| Forward Rate of Return (Yacktman) % | -18.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nanjing Hicin Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 505.194 | ||
| EPS (TTM) (Â¥) | 0.313 | ||
| Beta | 0.19 | ||
| Volatility % | 34.79 | ||
| 14-Day RSI | 53.69 | ||
| 14-Day ATR (Â¥) | 1.108556 | ||
| 20-Day SMA (Â¥) | 16.8335 | ||
| 12-1 Month Momentum % | -34.72 | ||
| 52-Week Range (Â¥) | 12.68 - 33 | ||
| Shares Outstanding (Mil) | 120 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nanjing Hicin Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nanjing Hicin Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nanjing Hicin Pharmaceutical Co Ltd Frequently Asked Questions
What is Nanjing Hicin Pharmaceutical Co Ltd(SZSE:300584)'s stock price today?
The current price of SZSE:300584 is ¥17.86. The 52 week high of SZSE:300584 is ¥33.00 and 52 week low is ¥12.68.
When is next earnings date of Nanjing Hicin Pharmaceutical Co Ltd(SZSE:300584)?
The next earnings date of Nanjing Hicin Pharmaceutical Co Ltd(SZSE:300584) is .
Does Nanjing Hicin Pharmaceutical Co Ltd(SZSE:300584) pay dividends? If so, how much?
Nanjing Hicin Pharmaceutical Co Ltd(SZSE:300584) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers